Sign in
4

Changes in Ownership

HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-25-018118

PRESIDENT AND CEO sold 60,000 shares at an average $53.09 ($3,185,280)

  • PRESIDENT AND CEO acquired 60,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Torley Helen PRESIDENT AND CEO 2025-06-20 Option exercise 10b5-1 +20,000 $8.11 $162,200 753,719 D
Torley Helen PRESIDENT AND CEO 2025-06-20 Sale 10b5-1 −20,000 $52.96 $1,059,200 733,719 D
Torley Helen PRESIDENT AND CEO 2025-06-23 Option exercise 10b5-1 +20,000 $8.11 $162,200 753,719 D
Torley Helen PRESIDENT AND CEO 2025-06-23 Sale 10b5-1 −20,000 $52.57 $1,051,460 733,719 D
Torley Helen PRESIDENT AND CEO 2025-06-24 Option exercise 10b5-1 +20,000 $8.11 $162,200 753,719 D
Torley Helen PRESIDENT AND CEO 2025-06-24 Sale 10b5-1 −4,489 $53.11 $238,406 749,230 D
Torley Helen PRESIDENT AND CEO 2025-06-24 Sale 10b5-1 −15,511 $53.91 $836,214 733,719 D
Derivatives
Torley Helen PRESIDENT AND CEO 2025-06-20 Option exercise · Option to Purchase Common Stock 10b5-1 −20,000 $8.11 $162,200 356,569 D
Torley Helen PRESIDENT AND CEO 2025-06-23 Option exercise · Option to Purchase Common Stock 10b5-1 −20,000 $8.11 $162,200 336,569 D
Torley Helen PRESIDENT AND CEO 2025-06-24 Option exercise · Option to Purchase Common Stock 10b5-1 −20,000 $8.11 $162,200 316,569 D
Open-market sales · 60,000 sh · avg $53.09 · $3,185,280
Loading xslF345X05/form4-06242025_090608.xml…